Chronic Obstructive Pulmonary Disease

ACCP COPD

ACCP COPD GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/61598

Contents of this Issue

Navigation

Page 8 of 9

Generic (Brand) Table 4. Quick Relief Medicationsa Dosage Form Short-acting β2 Albuterol (ProAir ® Proventil ® HFA, Ventolin ® HFA, Pirbuterol (Maxair® Autohaler® ) Levalbuterol (Xopenex ® Albuterol Generic (Proventil® Ventolin® ) (Ventolin Nebules® ) ) (AccuNeb® Levalbuterol (Xopenex ® MDI (Combivent ® Inhalation spray (Combivent ® Respimat ® ) Nebulizer solution (DuoNeb ® ) , HFA) 45 mcg/dose Nebulizer solutionb 1.25 mg in 3 mL 2.5 mg in 3 mL 0.5% (20 mL vials for dilution) 1 mg/mL ) 0.63 mg in 3 mL 1.25 mg in 3 mL 0.31, 0.63, 1.25 mg per 3 mL ) 18 mcg ipratropium/ 103 mcg albuterol per dose 20 mcg ipratropium/ 100 mcg albuterol per dose 0.5 mg ipratropium (0.017% in 3 mL)/ 2.5 mg albuterol (0.083% in 3 mL) 0.63-1.25 mg q6-8h prn 2 inh qid prn Max dose: 12 inh/d 2 inh qid Max: 6 inh/24 hrs 3 mL qid via nebulization Max: 6 doses/day a See product labeling for complete prescribing information. b Nebulizer medications are not therapy of choice for patients at home, but may be indicated under certain circumstances. 5 min 3-4 h 10-17 min Combinations (Use for acute bronchospasm. Some synergism with both agents.) Ipratropium/albuterol 5-8 h 1.25-5 mg q6-8h prn 10-15 min 4-6 h induced bronchospasm) MDI HFA) 200 mcg/dose Dose Onset Duration -agonists (use for relief of acute symptoms and prevention of exercise- 90 mcg/dose 2 inh q4-6h prn. In some patients 1 inh q4h may be sufficient 2 inh 15 min before exercise 2 inh q4-6h prn. In some patients 1 inh q4h may be sufficient Max dose: 12 inh/q24h 2 inh q4-6h prn. In some patients 1 inh q4h may be sufficient ≤ 15 min < 5 min 5-10 min 3-6 h 5 h 3-4 h For more information on FDA changes to MDIs containing CFCs (chlorofluorocarbons) please see http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm083812.htm and http://www.fda. gov/Drugs/DrugSafety/InformationbyDrugClass/ucm080446.htm.

Articles in this issue

Links on this page

Archives of this issue

view archives of Chronic Obstructive Pulmonary Disease - ACCP COPD